ArticleIDCases2026
Challenges in causality assessment of renal dysfunction during sequential treatment for presumed rifampicin-resistant tuberculosis in an elderly patient.
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal impairment during treatment for rifampicin-resistant tuberculosis (RR-TB) is uncommon but clinically significant, especially in elderly patients with limited physiological reserve. Determining whether renal dysfunction is attributable to anti-tuberculosis drugs or patient-related factors remains a major clinical challenge, particularly following sequential regimen changes. Case presentation: A 74-year-old man with a low body mass index (17.5 kg/m²) was treated for presumed RR-TB based on a single Xpert MTB/RIF assay showing rifampicin resistance despite persistently negative smear microscopy and mycobacterial culture. Baseline renal function was normal (serum creatinine 89 µmol/L; estimated glomerular filtration rate [eGFR] 73.2 mL/min/1.73 m²). Eighteen days after initiation of a long oral regimen (D2: levofloxacin, clofazimine, linezolid, pyrazinamide, and cycloserine), acute kidney injury developed, with serum creatinine increasing to 140 µmol/L and eGFR declining to 42.34 mL/min/1.73 m². The regimen was switched to BPaLM, during which renal function worsened with marked fluctuations (eGFR 24.65-57.3 mL/min/1.73 m²) Conclusion: This case highlights the complexity of evaluating renal dysfunction during sequential treatment for RR-TB. Advanced age, low BMI, frailty, and fluctuating hydration status should be considered when interpreting changes in renal function. Careful interpretation requires integration of the clinical course and available diagnostic information rather than reliance on temporal associations alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.